Valenti, Mario http://orcid.org/0000-0001-9140-9263
Gargiulo, Luigi
Ibba, Luciano
Malagoli, Piergiorgio
Amoruso, Fabrizio
Balato, Anna
Bardazzi, Federico
Burlando, Martina
Carrera, Carlo G.
Dapavo, Paolo
Dini, Valentina
Gaiani, Francesca M.
Girolomoni, Giampiero
Guarneri, Claudio
Lasagni, Claudia
Loconsole, Francesco
Marzano, Angelo V.
Maurelli, Martina
Megna, Matteo
Orsini, Diego
Travaglini, Massimo
Costanzo, Antonio
Narcisi, Alessandra
Article History
Received: 16 April 2024
Accepted: 2 May 2024
First Online: 15 May 2024
Declarations
:
: Mario Valenti has been a consultant and/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie and Boehringer Ingelheim. Luigi Gargiulo has been a consultant for Almirall, Pfizer and UCB. Luciano Ibba has been a consultant for Almirall. Piergiorgio Malagoli has been a speaker for AbbVie, Lilly, Novartis, Janssen-Cilag, Celgene, Leopharma, and Almirall. Anna Balato has received honoraria for participation in advisory boards, meetings, or as speaker for AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, Sanofi-Genzyme, and UCB Pharma. Federico Bardazzi has been a consultant advisor and clinical study investigator for Eli Lilly, AbbVie, Novartis, Leo Pharma, Sandoz, Bristol Myers, Abiogen-Pharma, Celgene and Janssen. Martina Burlando has acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, UCB Pharma. Carlo G. Carrera has served as a board participant or speaker for AbbVie, Lilly, Janssen, Novartis, Celgene, Almirall, and Leopharma. Francesca M. Gaiani acted as a speaker or consultant for Novartis, AbbVie, Eli Lilly, Celgene, LeoPharma, and Almirall. Paolo Dapavo has been a speaker for Novartis, AbbVie, Sanofi, UCB, Janssen, Lilly, and LeoPharma. Giampiero Girolomoni served as consultant and/or speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Eli-Lilly, LeoPharma, Novartis, Pfizer, Samsung, Sanofi and UCB. Claudio Guarneri has been a scientific consultant/speaker/clinical study investigator for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Almirall, LEO Pharma. Claudia Lasagni declares a conflict of interest with AbbVie, Novartis, Lilly and Almirall. Francesco Loconsole served on advisory boards and/or received honoraria for lectures from AbbVie, Janssen-Cilag, Novartis, Lilly, Sanofi. Angelo V. Marzano reports consultancy/advisory boards disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi and UCB. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, Janssen, Leo-Pharma, UCB and Novartis. Diego Orsini has been a speaker and/or consultant for AbbVie, LeoPharma, UCB, Bristol-Meyer-Squibb and Boehringer-Ingelheim. Antonio Costanzo has been a consultant and/or speaker for AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz, and UCB. Alessandra Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen and Boehringer Ingelheim. Fabrizio Amoruso, Valentina Dini, Martina Maurelli and Massimo Travaglini have nothing to disclose.
: Institutional review board approval was exempted as the study protocol did not deviate from standard clinical practice. All patients received ixekizumab as part of routine clinical practice in accordance with European guidelines. All included patients had provided written consent for retrospective study of data collected during routine clinical practice (demographics, clinical scores). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.